Quarterly ResultMay 12, 2026, 07:06 AM
ProQR Q1 Net Loss 13.4M; Cash 81.1M; Pipeline Advances
AI Summary
ProQR Therapeutics N.V. reported a net loss of 13.4 million for Q1 2026, an increase from 10.1 million in Q1 2025, with revenue decreasing to 2.0 million. The company ended the quarter with 81.1 million in cash and cash equivalents, providing a runway into mid-2027. Operationally, ProQR is on track for AX-0810 target engagement data in Q2 2026, selected biliary atresia as the initial Phase 2 indication, and is advancing multiple other pipeline programs towards clinical trials. The Axiomer platform is also being enhanced with AI-enabled discovery capabilities and a partnership with Ginkgo Bioworks.
Key Highlights
- Q1 2026 net loss increased to 13.4 million from 10.1 million in Q1 2025.
- Revenue for Q1 2026 was 2.033 million, down from 4.519 million in Q1 2025.
- Ended Q1 2026 with 81.1 million in cash and cash equivalents, supporting runway into mid-2027.
- Net cash used in operating activities was 11.1 million in Q1 2026, an improvement from 15.8 million in Q1 2025.
- AX-0810 target engagement data in healthy volunteers expected in Q2 2026; biliary atresia selected for Phase 2.
- AX-0811 CTA filing expected mid-2026, with initial clinical data by year-end 2026.
- AX-0422 CTA filing expected early 2027, with initial clinical data targeted for H1 2027.
- Axiomer platform enhanced with AI-enabled discovery and partnership with Ginkgo Bioworks.
Price Impact
More from PRQR